Last updated: October 27, 2026
Humulin 70/30 is a mature recombinant human insulin premix containing 70% insulin isophane suspension and 30% regular human insulin. Eli Lilly markets it as a U-100 injectable suspension for subcutaneous administration. The product has no meaningful remaining composition-of-matter exclusivity, faces competition from Novo Nordisk’s Novolin 70/30 and lower-priced human insulin channels, and generates limited standalone financial visibility because Lilly reports broader Humulin and insulin categories rather than Humulin 70/30 revenue.
What is Humulin 70/30 and how is it positioned?
Humulin 70/30 combines intermediate-acting NPH insulin with short-acting regular human insulin. It is intended to provide both basal and mealtime insulin coverage through a single premixed injection.
| Attribute |
Humulin 70/30 |
| Active ingredients |
70% insulin isophane human suspension, 30% regular human insulin |
| Strength |
U-100, 100 units/mL |
| Dosage form |
Injectable suspension |
| Route |
Subcutaneous injection |
| Reference company |
Eli Lilly and Company |
| FDA regulatory category |
Insulin biologic product |
| Primary alternatives |
Novolin 70/30, human insulin premixes, analog premixes |
| Commercial position |
Mature, low-cost human insulin product |
| Standalone revenue disclosure |
Not provided by Lilly |
Humulin 70/30 differs from analog premixes such as NovoLog Mix 70/30 and Humalog Mix 75/25. Human insulin premixes generally have slower onset and less flexible dosing than rapid-acting analog premixes, but their lower acquisition cost supports continued use in cost-sensitive markets and among patients with limited insurance coverage.
When did Humulin 70/30 receive FDA approval?
Humulin 70/30 was approved by the FDA under Lilly’s Humulin product franchise in the late 1980s. The product’s FDA regulatory history predates the current biosimilar framework and the 2020 transition of insulin products from the Federal Food, Drug, and Cosmetic Act to the Public Health Service Act.
The regulatory history matters commercially because Humulin 70/30 is not a recently launched biologic with a long remaining exclusivity period. Its market position depends on manufacturing scale, distribution, physician familiarity, payer access, and price rather than regulatory exclusivity.
The FDA’s transition rule moved insulin products regulated under section 505 of the Food, Drug, and Cosmetic Act into the section 351(a) biologic framework on March 23, 2020. That transition did not restore patent protection or create a new market exclusivity period for long-established products such as Humulin 70/30 (FDA, 2020).
What patents protect Humulin 70/30?
No commercially important unexpired composition patent is generally associated with Humulin 70/30. The core recombinant human insulin technology, the NPH/regular premix concept, and the underlying insulin sequence are decades old.
The relevant protection profile is:
| Protection category |
Current assessment |
| Insulin molecule patent |
Expired |
| NPH/regular premix concept |
Expired or not a meaningful exclusivity barrier |
| Original Humulin product patents |
Expired |
| Delivery-device patents |
May apply to specific devices, but not to the vial product broadly |
| Formulation patents |
No widely recognized, product-blocking exclusivity for the legacy U-100 suspension |
| Method-of-use patents |
No known commercially significant barrier to ordinary diabetes treatment |
| Regulatory exclusivity |
Expired |
| Manufacturing know-how |
Potentially important, but not a statutory market monopoly |
The absence of active patent protection does not make entry simple. Insulin manufacturing requires tightly controlled cell culture, purification, crystallization, formulation, sterility testing, analytical comparability, and validated filling operations. Those manufacturing requirements can create practical barriers even when legal exclusivity has ended.
What is the Orange Book status of Humulin 70/30?
Humulin 70/30 originated as an FDA-approved insulin product under the pre-transition drug framework. The Orange Book records patents and exclusivity associated with approved drug applications, but the commercially relevant patent estate for Humulin 70/30 is effectively exhausted.
The product’s current protection profile has three implications:
- A competitor does not need to wait for a future Humulin 70/30 patent expiration date.
- Any market entry strategy would focus on FDA approval, manufacturing comparability, supply reliability, and payer contracting.
- Paragraph IV litigation is unlikely to be the principal competitive mechanism for this mature premix.
The absence of a meaningful active patent estate also reduces the likelihood of a conventional branded-generic litigation cycle comparable with newer small-molecule drugs.
Are there Paragraph IV challenges to Humulin 70/30?
No major, widely reported Paragraph IV litigation campaign is associated with Humulin 70/30. That result is consistent with the product’s age and the lack of an important unexpired patent barrier.
The competitive pathway is more likely to involve:
- A biologic application under section 351(a) or 351(k);
- A product approved through an alternative insulin pathway;
- A branded human-insulin competitor;
- Pharmacy or wholesaler private-label distribution;
- Contract manufacturing and cash-pay sales.
Paragraph IV certification remains relevant to products with listed patents, but it has limited strategic importance for a mature insulin premix with no central blocking patent.
Is Humulin 70/30 exposed to biosimilar competition?
The product is exposed to biosimilar and follow-on biologic competition in principle, but the commercial threat is more complicated than for a high-priced injectable biologic.
Human insulin competitors
Novo Nordisk’s Novolin 70/30 is the closest branded competitor. It contains the same broad types of human insulin components and competes directly in the premixed human-insulin segment.
Biosimilar pathway
The FDA has approved insulin products through the biologic framework, including biosimilar and interchangeable insulin analogs. Semglee, an insulin glargine product, became the first interchangeable biosimilar insulin in the United States. Rezvoglar also received interchangeable biosimilar status for insulin glargine (FDA, 2021; FDA, 2022).
Those approvals demonstrate that insulin biosimilar competition is legally and technically feasible. They do not establish automatic substitutability for Humulin 70/30. A biosimilar to insulin glargine is not a substitute for a 70/30 human-insulin premix, which has a different active-ingredient structure, pharmacokinetic profile, and clinical use.
As of the latest broadly available FDA product information, no interchangeable biosimilar specifically matching the Humulin 70/30 premix has become a major U.S. competitor.
How does Humulin 70/30 compare with Novolin 70/30?
| Factor |
Humulin 70/30 |
Novolin 70/30 |
| Manufacturer |
Eli Lilly |
Novo Nordisk |
| Insulin type |
Human insulin premix |
Human insulin premix |
| Premix ratio |
70% NPH, 30% regular insulin |
70% NPH, 30% regular insulin |
| U.S. market role |
Mature branded product |
Direct branded competitor |
| Patent advantage |
None material |
None material |
| Main competitive lever |
Supply, contracting, brand familiarity |
Retail access, pricing, distribution |
| Cash-pay relevance |
High |
High |
| Biosimilar exposure |
Theoretical and future-oriented |
Theoretical and future-oriented |
The two products compete more on price and availability than on differentiated clinical performance. Pharmacy distribution, wholesaler inventory, Medicaid reimbursement, employer coverage, and cash-pay programs influence switching decisions.
What are the main market dynamics for Humulin 70/30?
The U.S. market is shaped by five forces.
Price compression
Human insulin is a mature category with substantial price pressure. Public attention to insulin affordability has pushed manufacturers, payers, pharmacies, and policymakers toward lower out-of-pocket costs.
Eli Lilly announced insulin affordability initiatives that reduced patient out-of-pocket exposure for eligible users and expanded access to lower-cost insulin options. The company has also used savings programs and affordability programs to reduce the effective price paid by certain patients (Eli Lilly and Company, 2023).
Price reductions can increase unit access while reducing revenue per vial. The net effect depends on payer mix, channel discounts, utilization, and whether lower prices expand the treated population.
Analog substitution
Rapid-acting and long-acting insulin analogs have displaced part of the human-insulin market because of dosing convenience, pharmacokinetic predictability, and reduced meal-timing constraints. Premixed analog products compete with Humulin 70/30 among patients seeking fewer injections or more flexible timing.
Cash-pay and uninsured demand
Humulin 70/30 remains relevant for uninsured and underinsured patients because human insulin is generally less expensive than analog insulin. Retail availability and cash pricing can therefore support demand even as higher-income and commercially insured patients migrate to analog products.
Government pricing pressure
Medicare insulin cost-sharing rules and broader federal drug-pricing policy reduce patient out-of-pocket costs for covered insulin products. These measures can raise adherence but may also reduce the commercial value of list-price differentiation.
Supply resilience
Insulin manufacturing is concentrated among a small number of multinational suppliers. Manufacturing interruptions, device or vial constraints, quality events, and wholesaler inventory changes can produce shortages or local availability problems. For a mature product, reliable supply is a material competitive asset.
What is the financial trajectory of Humulin 70/30?
Lilly does not publicly report revenue, gross margin, or operating profit for Humulin 70/30 as a standalone SKU. Its financial disclosures generally aggregate products within broader categories or report selected brands without separating every concentration, vial, pen, and premix presentation.
The likely financial profile is therefore:
| Financial driver |
Direction |
| Unit demand |
Stable to declining in developed markets |
| Net price |
Downward pressure |
| Gross margin |
Lower than for newer specialty medicines |
| Competitive intensity |
High |
| Manufacturing economics |
Scale-dependent |
| Revenue visibility |
Limited at individual-product level |
| Long-term growth potential |
Low |
| Cash-generation potential |
Positive if manufacturing and distribution remain efficient |
Humulin 70/30 is unlikely to be a material growth driver for Lilly’s current portfolio. Its economic value is more consistent with a mature cash-generating product that contributes recurring revenue through established manufacturing and distribution infrastructure.
Lilly’s financial growth has been driven primarily by newer medicines, including incretin-based therapies and selected specialty products. Compared with those franchises, Humulin 70/30 has lower pricing power, greater payer sensitivity, and limited ability to expand through premium differentiation.
What generic launch risks exist for Humulin 70/30?
The principal risk is not a patent-led generic launch. It is a low-price competitive entrant that obtains regulatory approval and uses retail, government, or private-label channels to undercut branded pricing.
A credible entrant would need:
- A validated insulin production platform;
- Demonstrated analytical and clinical comparability;
- Reliable sterile manufacturing;
- Sufficient capacity to avoid shortages;
- Distribution through wholesalers and pharmacies;
- Payer acceptance;
- A price low enough to compensate for limited brand recognition.
The strongest near-term threat is therefore from established insulin manufacturers rather than a small generic company with no biologic manufacturing infrastructure.
What licensing deals affect Humulin 70/30?
No major recent licensing transaction is publicly identified as a principal driver of Humulin 70/30’s economics. Lilly owns the Humulin brand and core commercial rights. The product’s mature status reduces the strategic rationale for licensing its rights to a third party.
Distribution agreements, wholesaler arrangements, government contracts, and pharmacy programs can affect realized sales without changing ownership of the underlying product.
What geographic markets are most important?
Humulin 70/30 is part of Lilly’s international insulin business, but market economics vary sharply by country.
| Market |
Commercial characteristics |
| United States |
High pricing scrutiny, strong Novolin competition, Medicaid and Medicare influence |
| Emerging markets |
Greater dependence on affordability, public procurement, and human insulin |
| Western Europe |
Mature reimbursement systems and strong analog penetration |
| Low-income markets |
Human insulin can remain clinically and economically important |
| Institutional channels |
Volume purchasing and tender pricing can compress margins |
The product’s strongest long-term demand profile is in markets where human insulin remains the affordability standard and analog substitution is limited.
How strong is the Humulin 70/30 patent estate?
The patent estate is weak as a current exclusivity asset but meaningful as a manufacturing and regulatory asset. Lilly’s advantages include:
- Long operating history;
- Established insulin manufacturing facilities;
- Brand recognition;
- Regulatory familiarity;
- Existing distribution;
- Experience managing insulin quality and supply.
Those advantages can delay or weaken competition, but they do not prevent approval of a technically comparable competitor. The product’s legal protection is therefore low, while its operational barriers remain moderate to high.
What is the likely generic entry scenario?
The most probable scenario is gradual price erosion rather than a single disruptive launch.
A new competitor could enter through a biosimilar or follow-on biologic pathway, but approval would not guarantee pharmacy substitution. Physicians and pharmacists may treat human premixes as clinically familiar products, yet reimbursement contracts and supply consistency would determine actual uptake.
The likely sequence is:
- Continued competition with Novolin 70/30.
- Ongoing cash-price reductions and affordability programs.
- Stable use in cost-sensitive patient groups.
- Gradual migration toward analog premixes where coverage permits.
- Potential follow-on biologic entry after sufficient commercial opportunity develops.
Key Takeaways
- Humulin 70/30 is a mature U-100 human-insulin premix owned and marketed by Eli Lilly.
- Its core patents and regulatory exclusivity have expired.
- No material Paragraph IV litigation campaign is associated with the product.
- Novolin 70/30 is the closest direct U.S. competitor.
- Biosimilar insulin competition is established for other insulin molecules, but no major interchangeable biosimilar specifically targeting Humulin 70/30 has emerged.
- Lilly does not disclose Humulin 70/30 revenue separately, preventing a precise product-level financial forecast.
- The product is likely a low-growth, price-sensitive contributor rather than a strategic growth asset.
- Manufacturing scale, quality systems, supply reliability, and distribution are more important than patent protection.
- The principal commercial risk is gradual price compression from branded human-insulin competitors, follow-on biologics, and lower-cost retail channels.
FAQs
Is Humulin 70/30 still commercially available?
Yes. Humulin 70/30 remains an FDA-approved human-insulin premix marketed by Eli Lilly, subject to product availability by presentation and market.
Is Humulin 70/30 interchangeable with Novolin 70/30?
They are closely comparable human-insulin premixes, but substitution depends on the specific product, labeling, pharmacy rules, prescriber direction, and clinical circumstances.
Does Humulin 70/30 have a biosimilar?
No major U.S. biosimilar specifically matching the Humulin 70/30 premix has become a significant commercial competitor based on FDA insulin-product information available through 2024.
Why has Humulin 70/30 not attracted major generic litigation?
Its core patent protection is old or expired, leaving little value in challenging a blocking patent. The main barriers are biologic manufacturing, FDA approval, supply reliability, and commercial scale.
Is Humulin 70/30 financially important to Eli Lilly?
It contributes recurring insulin revenue, but Lilly does not separately disclose Humulin 70/30 sales. Relative to Lilly’s newer incretin and specialty-medicine franchises, its growth and pricing potential are limited.
References
-
Eli Lilly and Company. (2023). Lilly insulins now available for $35 a month for people with commercial insurance and people without insurance. https://investor.lilly.com
-
U.S. Food and Drug Administration. (2020). Insulin transition plan for the Federal Food, Drug, and Cosmetic Act. https://www.fda.gov
-
U.S. Food and Drug Administration. (2021). FDA approves first interchangeable biosimilar insulin product. https://www.fda.gov
-
U.S. Food and Drug Administration. (2022). FDA approves second interchangeable biosimilar insulin product. https://www.fda.gov
-
U.S. Food and Drug Administration. (n.d.). Orange Book: Approved drug products with therapeutic equivalence evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/
-
U.S. Food and Drug Administration. (n.d.). DailyMed: Humulin 70/30 insulin human injection, suspension. National Library of Medicine. https://dailymed.nlm.nih.gov
